Regulation of HER signalling through combinatorial receptor interactions
Abstract
Receptor dimerization and ligand identity shape the signalling specificity of the human epidermal growth factor receptor (HER) family. This Review explores the roles of receptor–receptor and receptor–ligand interactions in downstream pathway engagement, signalling dynamics and receptor dysregulation in cancer. The human epidermal growth factor receptor (HER) family of receptor tyrosine kinases, which includes EGFR (also referred to as HER1 or ErbB1), HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4), constitutes an essential signalling network that regulates key cellular behaviours and is frequently dysregulated in cancer. Although HER receptor heterodimerization has long been recognized as a central organizing principle of this network, the mechanisms that determine receptor pairing and translate distinct receptor–ligand combinations into specific signalling outputs remain incompletely understood. This Review examines HER receptor dimerization preferences, their modulation by ligand identity and the mechanisms governing these interactions revealed by recent structural studies. We discuss how HER heterodimers engage major downstream pathways and how signalling is shaped by temporal dynamics, ligand-specific and dimer-specific pathway activation, and receptor trafficking and downregulation. Finally, we consider how receptor overexpression, oncogenic mutations and targeted therapies reconfigure HER receptor interactions to generate ligand-independent signalling, enhance oncogenic output and promote therapeutic resistance.